

**PB 139 of 2024**

**National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024
(No. 12)**

*National Health Act 1953*

I, EDEN SIMON, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 19 December 2024

**EDEN SIMON**

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015). 2

1 Name

1. This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 12)*.
2. This instrument may also be cited as PB 139 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 January 2025* | *1 January 2025* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)*

1. Schedule 1, entry for Acalabrutinib

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Capsule 100 mg | 20 | 56 | 5 |  |

1. Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate)

*omit from the column headed “Form”:* Tablet (enteric coated) 20 mg (as magnesium trihydrate)

*substitute:* Tablet (enteric coated) 20 mg (as magnesium)

1. Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate)

*omit from the column headed “Form”:* Tablet (enteric coated) 40 mg (as magnesium trihydrate)

*substitute:* Tablet (enteric coated) 40 mg (as magnesium)

1. Schedule 1, after entry for Tafamidis

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Talazoparib | Capsule 100 micrograms (as tosilate) | 20 | 30 | 5 |  |
|  | Capsule 250 micrograms (as tosilate) | 20 | 30 | 5 |  |
|  | Capsule 350 micrograms (as tosilate) | 20 | 30 | 5 |  |
|  | Capsule 500 micrograms (as tosilate) | 20 | 30 | 5 |  |

1. Schedule 2, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate)

*omit from the column headed “Form”:* Tablet (enteric coated) 20 mg (as magnesium trihydrate)

*substitute:* Tablet (enteric coated) 20 mg (as magnesium)

1. Schedule 2, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate)

*omit from the column headed “Form”:* Tablet (enteric coated) 40 mg (as magnesium trihydrate)

*substitute:* Tablet (enteric coated) 40 mg (as magnesium)